Lynparza is a first-in-class oral poly ADP
ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment.
A more recent treatment strategy involves the use of a class of small molecules developed to inhibit poly ADP
ribose polymerase (PARR).
NASDAQ: BMRN) have entered into an asset purchase agreement under which Medivation will acquire all worldwide rights to talazoparib (formerly referred to as BMN 673), an orally-available poly ADP
ribose polymerase inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer, the companies said.
The poly ADP
ribose polymerase (PARP) protein plays a role in the repair of single-strand breaks.
The results of an Oregon Health and Science University Knight Cancer Institute study have prompted additional exploration into whether the patient population included in clinical trials for drugs that target the enzyme poly ADP
ribose polymerase (PARP) should be expanded.
Olaparib (AZD2281 / KU-0059436) is an investigational Poly ADP
ribose polymerase (PARP) inhibitor being evaluated in phase II clinical studies for the treatment of certain types of ovarian and breast cancer.
The product is an investigational, oral and dual-mechanism poly ADP
ribose polymerase inhibitor, which is taken once daily.
today announced Phase 2 data showing that its investigational, dual-mechanism poly ADP
ribose polymerase (PARP) inhibitor, talazoparib, demonstrated anti-tumor activity in patients with germline (inherited) BRCA1/2-positive (gBRCA+) advanced breast cancer.
The drug is an innovative, first-in-class oral poly ADP
ribose polymerase (PARP) inhibitor.
Medivation, a United States-based biopharmaceutical company, has agreed to acquire all global rights of BioMarin Pharmaceutical's talazoparib, a highly-potent, orally-available poly ADP
ribose polymerase inhibitor, it was reported yesterday.
His responsibilities also included the in-licensing and global clinical development of the poly ADP
ribose polymerase inhibitor, talazoparib.
AstraZeneca today announced enrollment of the first patient in the Phase III clinical programme for olaparib, an innovative oral poly ADP
ribose polymerase (PARP) inhibitor being investigated for the treatment of BRCA mutated ovarian cancer.